Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
SLC22A17 Mouse anti-Human, Clone: OTI2D6, liquid, TrueMAB™
Mouse Monoclonal Antibody
Supplier: OriGene TA810195
SDSDocumentsProduct Certifications Promotions
DescriptionThe Slc22 family of organic anion and cation transporters (OATs, OCTs, OCTNs) are transmembrane proteins expressed predomitly in kidney and liver. Each contain 12 predicted alpha-helical transmembrane domains (TMDs) and one large extracellular loop between TMDs 1 and 2. Transporters of the SLC22 family function in different ways such as uniporters that mediate facilitated diffusion in either direction (OCTs), as anion exchangers (OAT1, OAT3 and URAT1), and as Na(+)/l-carnitine cotransporter (OCTN2). Slc22 family members participate in the absorption and/or excretion of drugs, xenobiotics, and endogenous compounds in intestine, liver, and kidney, and perform homeostatic functions in brain and heart. Mutations in the Slc22 family may cause specific diseases such as primary systemic carnitine deficiency or idiopathic renal hypouricemia and may change drug absorption or excretion. Recent studies show the expression of Slc22A17 as receptor for Lipocalin 2 is relatively high in hematopoietic stem cells.
|PBS with 1% BSA, 50% glycerol and 0.02% sodium azide|
|Human recombit protein fragment corresponding to amino acids 241-300 of human SLC22A17 produced in E.coli.|
|Immunohistochemistry (Paraffin), Western Blot|
|24p3R, BOCT, BOIT, NGALR, NGALR2, NGALR3, hBOIT|
|-20° C, Avoid Freeze/Thaw Cycles|
Provide Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok